Pompe. Lysosomal Disorders. Introduction
|
|
- Kenneth Merritt
- 5 years ago
- Views:
Transcription
1 Introduction disease is an inherited, genetic disorder which results in the lack of an enzyme 'acid alpha-glucosidase. disease is also known as acid maltase deficiency or glycogen storage disease type II. To understand the implications of this it is useful to know a little about this enzymes normal activity. The human body contains many different types of cells. A basic cell has many components as you can see from the diagram below, including the nucleus which contains chromosomes. Within the cell there is a small compartment called the lysosome - this contains all the enzymes the cell needs to manage its recycling of waste products. The enzymes in the lysosome begin the process of breaking down glycogen but in disease this is ineffective. The glycogen accumulates in various types of muscle skeletal (eg limb, body & respiratory muscle), smooth (eg the muscles involved in feeding/swallowing) and cardiac (heart muscle predominantly in children). Inheritance Page 1
2 disease is an inherited genetic disorder described medically as an 'autosomal recessive disease. Each person has 23 pairs of chromosomes which contain genes they receive 1 set from each parent. Genes contain the necessary information to allow our body to be formed and to function. It is estimated that every human being has 8-10 genes that have changes within them (called mutations) however only some can cause disease. disease only produces symptoms when both copies of the gene are affected. This may well have occurred when both parents have 1 copy of the genetic mutation. They are said to be carriers (ie without any evidence of disease) but their offspring may inherit both copies of the faulty gene. There are other possibilities eg if 1 parent has disease and the other either has no mutation or is a carrier. In the former case all the children will be carriers and the latter there is a 50% chance of having an affected child and a 50% chance of a carrier. If you would like further information about the inheritance pattern in your personal circumstances or to know whether it is likely that any other members of your family are affected please discuss this with your physician or specialist nurse. Symptoms The signs and symptoms of disease are directly related to the muscles affected. The disease is progressive in nature, and affects proximal, respiratory and cardiac (infants) muscle. There are currently thought to be 2 main types of disease: Infantile Classic infantile is the most severe end of the spectrum with rapidly progressive cardiomegaly (enlarged heart) hepatomegaly (enlarged liver) weakness and hypotonia ('floppy ). This leads to early death usually in the first year of life Infantile variant has a slower progression and less severe cardiomegaly. It Page 2
3 usually presents during the first year of life Late onset Juvenile pompe presents later than infancy and typically does not include severe cardiomyopathy Adult onset is characterised by a slowly progressive myopathy (muscle weakness) that presents as an adult The severity of the disease and the rate of disease progression varies from person to person. Listed below are the possible symptoms: Page 3
4 Cardiomegaly (enlarged heart) Lysosomal Cardiomyopathy Disorders (weak heart) rarely seen Profound/rapidly progressive - hypotonia (floppy baby) Delayed motor milestones Frequent infections Respiratory insufficiency Cardio-respiratory failure (death) Failure to thrive, feeding difficulties Organomegaly enlarged liver, spleen & tongue Progressive proximal muscle weakness (esp. trunk and lower limbs) Gait abnormalities Muscle pain Difficulty climbing stairs Frequent falls Scapular winging Respiratory failure/insufficiency Morning headache & day time tiredness Orthopnea ( breathing difficulties when laying down) Sleep apnea ( stopping breathing whilst asleep) Exertional shortness of breath Respiratory infections Jaw muscle fatigue & swallowing difficulties At risk of food aspiration Weight stability Osteoporosis/osteopenia Neurological & hearing impairment Osteoporosis/osteopenia Adult onset Infantile onset Treatment Enzyme replacement therapy (ERT) Until recently in the UK treatment for disease was limited to supportive therapy. In April 2006 Genzyme corporation received a product licence for Myozyme. This is the direct replacement of the missing enzyme in disease a treatment known as enzyme Page 4
5 replacement therapy (ERT) This is an intravenous infusion that is give once per fortnight initially in hospital but with the possibility of home infusion if hospital infusions are uneventful. The infusion takes between 4-5 hours to give. This treatment is considered to be an orphan drug" and as such prescribing in England is restricted to NCG centres. In Scotland, Wales and N Ireland, permission must be obtained from the devolved NHS authorities in each region. Side effects are generally mild but may include: Hypersensitivity anaphylactic shock has been reported in a few patients Infusion reactions agitation, tremor, tachycardia (fast heart rate), cyanosis, flushing, hypertension (high blood pressure), pallor, tachypnoea (fast breathing), cough, vomiting, urticaria (rash), fever, rigors (chills), decreased oxygen saturation, hypotension (low blood pressure) & tachycardia (fast heart rate) Note: reactions are more likely if a patient has an acute underlying illness at the time of the Page 5
6 infusion, or if they have reacted to myozyme before. Supportive treatment This will vary considerably depending upon the nature and severity of the symptoms experienced. is a progressive disorder and therefore requires regular assessment to identify which treatments are appropriate. In general these tests should include assessment of cardiac and respiratory function (heart and lung), muscle strength and function, safety when swallowing and diet/weight maintenance. It is likely that people affected by pompe will also need to visit other doctors eg a neurologist, respiratory and/or cardiac physician as well as other healthcare professionals such as the physiotherapist, occupational therapist, speech therapist and dietician. At Addenbrooke s, patients are cared for by an experienced metabolic physician and a specialist nurse who will co-ordinate assessment, treatment and supportive care as necessary, with access to the multi disciplinary team. The input and support of a local physician is also essential. It is considered important for patients to adopt a healthy lifestyle by following dietary advice, exercising within limits and to avoid smoking in order to maintain or improve general health. Page 6
Understanding Late-Onset Pompe Disease
Understanding Late-Onset Pompe Disease What Is a Lysosome? Millions of tiny units called cells make up the human body. Each cell has its own job to keep the body running. Within each cell, there are organelles,
More informationPompe Disease. Family Education Booklet. Division of Pediatric Genetics Metabolism and Genomic Medicine
Pompe Disease Family Education Booklet Division of Pediatric Genetics Metabolism and Genomic Medicine Table of Contents What is Pompe disease?... 1 How common is Pompe disease?... 1 Basic genetic concepts...
More informationWhat s New in Newborn Screening?
What s New in Newborn Screening? Funded by: Illinois Department of Public Health Information on Newborn Screening Newborn screening in Illinois is administered by the Illinois Department of Public Health.
More informationMedication Policy Manual. Topic: Lumizyme, alglucosidase alfa Date of Origin: February 17, 2015
Medication Policy Manual Policy No: dru392 Topic: Lumizyme, alglucosidase alfa Date of Origin: February 17, 2015 Committee Approval Date: March 13, 2015 Next Review Date: March 2016 Effective Date: July
More informationDEVELOPING A FOLLOW-UP FRAMEWORK FOR POMPE DISEASE
DEVELOPING A FOLLOW-UP FRAMEWORK FOR POMPE DISEASE Presenter: Sarah Bradley, MS, CGC Genetic Counselor, NYS Newborn Screening Program Authors: S. Bradley, D. Kronn, B. Vogel, M. Caggana, J. Orsini, K.
More informationThere are four different forms of Tarui disease, which are classed by their signs and symptoms and age of presentation.
Tarui Disease Tarui disease (also known as phosphofructokinase deficiency, or glycogen storage disease type VII) was first described in 1965 by the Japanese physician Seiichiro Tarui and his co-workers.
More informationLSD WORKSHOP WHAT EVERY PEDIATRICIAN SHOULD KNOW. Amal Al Tenaiji Pediatric Metabolic Genetics SKMC Abu Dhabi
LSD WORKSHOP WHAT EVERY PEDIATRICIAN SHOULD KNOW Amal Al Tenaiji Pediatric Metabolic Genetics SKMC Abu Dhabi CASE A 1 month old infant presents with difficulty feeding and respiratory distress. Mom and
More informationWhat s New in Newborn Screening?
What s New in Newborn Screening? Funded by: Illinois Department of Public Health Information on Newborn Screening Newborn screening in Illinois is mandated and administered by the Illinois Department of
More informationSpinal Muscular Atrophy: Case Study. Spinal muscular atrophy (SMA) is a fairly common genetic disorder, affecting
Spinal Muscular Atrophy: Case Study Spinal muscular atrophy (SMA) is a fairly common genetic disorder, affecting approximately one in 6,000 babies. It is estimated that one in every 40 Americans carries
More informationswine flu vaccination:
swine flu vaccination: what you need to know Flu. Protect yourself and others. Contents What is swine flu?...................3 About the swine flu vaccine...........4 What else do I need to know?.........8
More informationwhat you need flu. Protect yourself and others.
swine flu vaccination: what you need to know flu. Protect yourself and others. contents What is swine flu?................ 3 About the swine flu vaccine........ 4 What else do I need to know?....... 8
More informationA Lawyer s Perspective on Genetic Screening Performed by Cryobanks
A Lawyer s Perspective on Genetic Screening Performed by Cryobanks As a lawyer practicing in the area of sperm bank litigation, I have, unfortunately, represented too many couples that conceived a child
More informationMuscular Dystrophies. Pinki Munot Consultant Paediatric Neurologist Great Ormond Street Hospital Practical Neurology Study days April 2018
Muscular Dystrophies Pinki Munot Consultant Paediatric Neurologist Great Ormond Street Hospital Practical Neurology Study days April 2018 Definition and classification Clinical guide to recognize muscular
More informationDNA Day Illinois 2013 Webinar: Newborn Screening and Family Health History. Tuesday, April 16, 2013
DNA Day Illinois 2013 Webinar: Newborn Screening and Family Health History Tuesday, April 16, 2013 Objectives Recognize the importance & impact of newborn screening Describe the process of newborn screening
More informationFatty Acid Oxidation Disorders
Genetic Fact Sheets for Parents Fatty Acid Oxidation Disorders Screening, Technology, and Research in Genetics is a multi-state project to improve information about the financial, ethical, legal, and social
More informationFatty Acids Synthesis L3
Fatty Acids Synthesis L3 The pathway for fatty acid synthesis occurs in the cytoplasm, whereas, oxidation occurs in the mitochondria. The other major difference is the use of nucleotide co-factors. Oxidation
More informationANAPHYLAXIS Following Vaccination. A Severe Adverse Event. Developed for the Grampians Infection Control Group (GRICG) Version 2.
ANAPHYLAXIS Following Vaccination A Severe Adverse Event Developed for the Grampians Infection Control Group () Version 2.0:2014 Adverse Event Following Immunisation Adverse event following immunisation
More informationMuscular Dystrophy UK s Adult North Star Network. Care recommendations for adults with Duchenne a consultation
Muscular Dystrophy UK s Adult North Star Network Care recommendations for adults with Duchenne a consultation Background: The North Star Network was set up in 2003 to help drive improvements in services
More informationFatty Acid Oxidation Disorders
Genetic Fact Sheets for Parents Fatty Acid Oxidation Disorders Screening, Technology, and Research in Genetics is a multi-state project to improve information about the financial, ethical, legal, and social
More informationINTRODUCTION. 1.
KRABBE DISEASE INTRODUCTION Krabbe disease is a genetic defect that affects the nervous system. It is caused by the shortage (deficiency) of an enzyme called galactosylceramidase. This enzyme deficiency
More informationThe Changing Face of Infantile Pompe Disease: A Report of Five Patients from the UAE
JIMD Reports DOI 10.1007/8904_2012_148 RESEARCH REPORT The Changing Face of Infantile Pompe Disease: A Report of Five Patients from the UAE Waseem Fathalla Elamin Ahmed Received: 02 July 2011 /Revised:
More informationClinical Summaries. CLN1 Disease, infantile onset and others
Clinical Summaries CLN1 Disease, infantile onset and others The gene called CLN1 lies on chromosome 1. CLN1 disease is inherited as an autosomal recessive disorder, which means that both chromosomes carry
More informationTHE FOUNDATION OF MORQUIO A MANAGEMENT
VIMIZIM THE FOUNDATION OF MORQUIO A MANAGEMENT A comprehensive guide to help you manage your condition Life-threatening allergic reactions, known as anaphylaxis, can occur during VIMIZIM infusions. Typical
More informationAnaphylaxis: Treatment in the Community
: Treatment in the Community is likely if a patient who, within minutes of exposure to a trigger (allergen), develops a sudden illness with rapidly progressing skin changes and life-threatening airway
More informationGUIDELINES FOR WEIGHT-BASED DOSING AND INFUSION
GUIDELINES FOR WEIGHT-BASED DOSING AND INFUSION Includes Example dose calculation wheel Preparation and administration information for healthcare professionals Please see enclosed full Prescribing Information,
More informationTHE FOUNDATION OF MORQUIO A MANAGEMENT
VIMIZIM (elosulfase alfa) THE FOUNDATION OF MORQUIO A MANAGEMENT A comprehensive guide to help you manage your condition Life-threatening allergic reactions, known as anaphylaxis, can occur during VIMIZIM
More informationMyotubular (centronuclear) myopathy
Myotubular (centronuclear) myopathy Myotubular, or centronuclear, myopathy falls under the umbrella of congenital myopathies. It is characterised by a specific pattern in the muscle tissue when viewed
More informationB1 Question 1 Foundation
B1 Question 1 Foundation The nucleus controls the activities of a cell. The instructions for how an organism develops i.e. the genes are found in the nuclei of its cells B1 Question 2 Foundation The genes
More information+ Color Change - + Hearing Loss - + Apnea - + Enuresis (urine - + Tremors - + Rash -
Review of Systems: 0-1 year old Constitution neg Eyes neg GI neg Neurological neg + Activity Change - + Eye Discharge - + Reflux - + Facial Asymmetry - + Appetite Change - + Eye Redness - + Vomiting -
More informationRobotic-assisted lingual tonsillectomy for sleep apnoea
Robotic-assisted lingual tonsillectomy for sleep apnoea You have been given this leaflet because you have been referred for a robotic-assisted lingual tonsillectomy for sleep apnoea. This leaflet offers
More informationMultiple System Atrophy
Multiple System Atrophy This document has been prepared to help you become more informed about Multiple System Atrophy. It is designed to answer questions about the condition and includes suggestions on
More informationAutoimmune lymphoproliferative syndrome (ALPS)
ALPS Autoimmune lymphoproliferative syndrome (ALPS) Information for families hello@piduk.org 0800 987 8986 www.piduk.org About this leaflet This leaflet is designed to help answer the questions families
More informationAnaphylaxis: treatment in the community
: treatment in the community Item Type Guideline Authors Health Service Executive Citation Health Service Executive. : treatment in the community. Dublin: Health Service Executive;. 5p. Publisher Health
More informationPackage leaflet: Information for the user. Myozyme 50 mg powder for concentrate for solution for infusion Alglucosidase alfa
Package leaflet: Information for the user Myozyme 50 mg powder for concentrate for solution for infusion Alglucosidase alfa Read all of this leaflet carefully before you start using this medicine because
More informationPackage leaflet: Information for the user. Elaprase 2 mg/ml concentrate for solution for infusion idursulfase
Package leaflet: Information for the user Elaprase 2 mg/ml concentrate for solution for infusion idursulfase This medicine is subject to additional monitoring. This will allow quick identification of new
More informationOpinion 9 January 2013
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 9 January 2013 The draft opinion adopted by the Transparency Committee on 7 November 2012 was the subject of a hearing
More informationNemaline (rod) myopathies
Nemaline (rod) myopathies Nemaline, or rod, myopathies are a group of conditions which fall under the umbrella of congenital myopathies. They are characterised by rod-like structures in the muscle cells,
More informationPROCEDURE FOR MANAGING AN ANAPHYLACTIC EMERGENCY
MULTIDISCIPLINARY PROCEDURE PROCEDURE FOR MANAGING AN ANAPHYLACTIC EMERGENCY First Issued June 2011 Issue Version Four Purpose of Issue/Description of Change Planned Review Date To promote safe and consistent
More information1/28/2019. OSF HealthCare INI Care Center Team. Neuromuscular Disease: Muscular Dystrophy. OSF HealthCare INI Care Center Team: Who are we?
Neuromuscular Disease: Muscular Dystrophy Muscular Dystrophy Association (MDA) and OSF HealthCare Illinois Neurological Institute (INI) Care Center Team The Neuromuscular clinic is a designated MDA Care
More informationThis leaflet answers some common questions about HERCEPTIN SC. It does not contain all the available information.
Consumer Medicine Information HERCEPTIN SC Trastuzumab 600 mg/5 ml solution for subcutaneous injection What is in this leaflet This leaflet answers some common questions about HERCEPTIN SC. It does not
More informationThis fact sheet describes the condition Fragile X and includes a discussion of the symptoms, causes and available testing.
11111 Fact Sheet 54 FRAGILE X SYNDROME This fact sheet describes the condition Fragile X and includes a discussion of the symptoms, causes and available testing. In summary Fragile X is a condition caused
More informationANAPHYLAXIS. Following Vaccination of Adults. A Severe Adverse Event
ANAPHYLAXIS Following Vaccination of Adults A Severe Adverse Event Developed for the Grampians Infection Control Group () Version 3.0:2018 Target audience This information package is for nurse immunisers
More informationNewborn screening for congenital metabolic diseases Optional out-of-pocket tests Information Sheet
Newborn screening for congenital metabolic diseases Optional out-of-pocket tests Information Sheet Website:www.tipn.org.tw Telephone:(02)85962050 Ext. 401-403 Service line:(02)85962065 Fax:(02)85962067
More informationREAD THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. (em-plis-city)
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION Pr Empliciti TM (em-plis-city) (elotuzumab 300 & 400 mg powder for concentrate for solution for infusion) Read this
More informationPackage leaflet: Information for patient
Package leaflet: Information for patient Apresoline Ampoules 20mg Powder for concentrate for solution for injection or infusion Hydralazine hydrochloride Read all of this leaflet carefully before you start
More informationTreatment Strategies for a Complex
Treatment Strategies for a Complex Neuromuscular Disease: The Pompe Story Barry J. Byrne, MD, PhD Pediatrics and Powell Gene Therapy Center University of Florida, College of Medicine 2 4 Initial Presentation
More informationInheritance of Gaucher Disease
Sarah Mother of a child with Gaucher Working toward a healthy future Helping her son achieve his own dreams, too Straight Talk For Patients and Families Inheritance of Gaucher Disease Genzyme Corporation
More informationProduct Information BROWN SNAKE ANTIVENOM AUST R 74897
Product Information APPROVED NAME BROWN SNAKE ANTIVENOM AUST R 74897 DESCRIPTION BROWN SNAKE ANTIVENOM is prepared from the plasma of horses immunised with the venom of the brown snake (Pseudonaja textilis).
More informationOSA in children. About this information. What is obstructive sleep apnoea (OSA)?
About this information This information explains all about sleep-related breathing problems in children, focusing on the condition obstructive sleep apnoea (OSA). It tells you what the risk factors are
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Myozyme 50 mg powder for concentrate for solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One vial contains
More informationMedical Specialists. SPECIALTY (type in contact name and phone number)
Medical Specialists SPECIALTY (type in contact name and phone number) Cardiothoracic Surgeon or Cardiovascular Surgeon Pediatric Cardiologist DESCRIPTION A physician specializing in surgical procedures
More informationBEVACIZUMAB (AVASTIN ) & Paclitaxel PROTOCOL
Bevacizumab (Avastin ) & Paclitaxel The treatment of Advanced Breast Cancer DRUG ADMINISTRATION Da Drug Daily Dose Route Diluent & Rate y 250mls Sodium Day 1,15 Bevacizumab 10 mg/kg Infusion Chloride 0.9%*
More informationAmino Acid Disorders. What is ASAL deficiency? Genetic Fact Sheets for Parents
Genetic Fact Sheets for Parents Amino Acid Disorders Screening, Technology, and Research in Genetics is a multi-state project to improve information about the financial, ethical, legal, and social issues
More informationInformation leaflet for patients and families. Huntington Disease (HD)
Information leaflet for patients and families Huntington Disease (HD) Introduction Huntington disease, or Huntington Chorea, (HD) is a slowly progressive disorder of the brain in adults. HD is an inherited
More informationInborn Error Of Metabolism :
Inborn Error Of Metabolism : Inborn Error Of Metabolism inborn error of metabolism are a large group of hereditary biochemical diseases in which specific gene mutation cause abnormal or missing proteins
More informationNeonatal and infant health. What to look out for in babies up to 6 months old. Anoo Jain Neonatal Consultant
Neonatal and infant health What to look out for in babies up to 6 months old Anoo Jain Neonatal Consultant CONTEXT Obstetrics Local & Regional Maternal Medicine Fetal Medicine NICU Genetics/ENT/Gynae Content
More informationswine flu vaccination:
swine flu vaccination: information for parents of children over six months and under five years old Flu. Protect yourself and others. Contents About this leaflet......................... 3 What is swine
More informationSummary of the risk management plan (RMP) for Ristempa (pegfilgrastim)
EMA/183255/2015 Summary of the risk management plan (RMP) for Ristempa (pegfilgrastim) This is a summary of the risk management plan (RMP) for Ristempa, which details the measures to be taken in order
More informationMedical Advisory Council: Verified
What is White Sutton Syndrome? White Sutton Syndrome (WHSUS) is a condition characterized by autism and developmental delay and/or intellectual disability, as well as a characteristic facial profile. Children
More informationWhat You Need to Know About LEMTRADA (alemtuzumab) Treatment: A Patient Guide
For Patients What You Need to Know About LEMTRADA (alemtuzumab) Treatment: A Patient Guide Patients: Your doctor or nurse will go over this patient guide with you. It is important to ask any questions
More informationINVESTIGATION OF ADVERSE TRANSFUSION REACTIONS TABLE OF RECOMMENDED TESTS. Type of Reaction Presentation Recommended Tests Follow-up Tests
Minor Allergic (Urticarial) Urticaria, pruritis, flushing, rash If skin reaction only and mild hives/ rash
More informationAll about the adult cystic fibrosis service
All about the adult cystic fibrosis service All about the adult cystic fibrosis service Lay Introduction to Cystic Fibrosis Service Specification Since April 2013, NHS England has taken on direct responsibility
More informationCost-effectiveness of sebelipase alfa (Kanuma ) for the treatment of lysosomal acid lipase (LAL) deficiency infantile paediatric adult
Cost-effectiveness of sebelipase alfa (Kanuma ) for the treatment of lysosomal acid lipase (LAL) deficiency The NCPE has issued a recommendation regarding the cost-effectiveness of sebelipase alfa (Kanuma
More informationCardiac Considerations and Care in Children with Neuromuscular Disorders
Cardiac Considerations and Care in Children with Neuromuscular Disorders - importance of early and ongoing treatment, management and available able medications. Dr Bo Remenyi Department of Cardiology The
More informationMabThera. SC. The wait is over. MabThera delivered in just 5 minutes. SC= subcutaneous injection
MabThera SC. The wait is over. MabThera delivered in just 5 minutes Abbreviated Prescribing Information MabThera 1400 mg solution for subcutaneous (SC) injection (Rituximab) Indications: Indicated in adults
More informationManagement of an immediate adverse event following immunisation
Management of an immediate adverse event following immunisation The vaccinated person should remain under observation for a short interval to ensure that they do not experience an immediate adverse event.
More informationDatabase of Adverse Event Notifications - medicines
Database of Adverse Event Notifications - medicines You searched for the following 3 medicines between 01/01/2017 01/01/2018: Ferinject 100mg/2mL (Ferric carboxymaltose) Ferinject 500mg/10mL (Ferric carboxymaltose)
More informationHYPERTROPHIC CARDIOMYOPATHY
HYPERTROPHIC CARDIOMYOPATHY Most often diagnosed during infancy or adolescence, hypertrophic cardiomyopathy (HCM) is the second most common form of heart muscle disease, is usually genetically transmitted,
More informationYour Mepact (mifamurtide) treatment and what to expect from it. Information for patients who have been prescribed mifamurtide for osteosarcoma.
Your Mepact (mifamurtide) treatment and what to expect from it. Information for patients who have been prescribed mifamurtide for osteosarcoma. Introduction to Mepact (mifamurtide) Mepact, also known as
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: nusinersen_spinraza 03/2017 10/2017 10/2018 10/2017 Description of Procedure or Service Spinal muscular atrophy
More informationPATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Atezolizumab PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL NAME/STAMP:
More informationWilson's Disease. A Guide. An explanation of what Wilson's disease is, symptoms, diagnosis and treatment
A Guide An explanation of what Wilson's disease is, symptoms, diagnosis and treatment What is Wilson's disease?... 4 Why does the body contain copper?... 4 What causes Wilson s disease?... 5 Are males
More informationSleep History Questionnaire
Sleep History Questionnaire Name: DOB: Phone: Date of Consultation: Consultation is requested by: Primary care provider: _ Preferred pharmacy: Chief complaint: Please tell us why you are here: How long
More informationHereditary Haemochromatosis For GPs
Hereditary Haemochromatosis For GPs What is Hereditary Haemochromatosis? Hereditary Haemochromatosis () is a common autosomal recessive disease resulting in excessive absorption of dietary iron from the
More informationBEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE SHARED CARE GUIDELINE FOR THE USE OF RILUZOLE IN THE TREATMENT OF MOTOR NEURONE DISEASE
BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE SHARED CARE GUIDELINE FOR THE USE OF RILUZOLE IN THE TREATMENT OF MOTOR NEURONE DISEASE PATIENT S NAME: PATIENT S ADDRESS: HOSPITAL NAME AND NUMBER /
More informationFriday, January 4. Bell Work:
Friday, January 4 Bell Work: Red green colorblindness is an X linked trait and is recessive. A male who is normal marries a woman who is a carrier, what is the phenotypic ratio of their offspring? 1 Genetic
More informationPKU TEMPLE. Tools Enabling Metabolic Parents LEarning ADAPTED AND ENDORSED BY ASIEM FOR USE IN ANZ DESIGNED AND ADAPTED BY THE DIETITIANS GROUP
TEMPLE Tools Enabling Metabolic Parents LEarning ADAPTED AND ENDORSED BY ASIEM FOR USE IN ANZ Australasian Society for Inborn Errors of Metabolism DESIGNED AND ADAPTED BY THE DIETITIANS GROUP PKU British
More informationTEMPLE. Tools Enabling Metabolic Parents LEarning ADAPTED BY THE DIETITIANS GROUP. British Inherited Metabolic Diseases Group
TEMPLE Tools Enabling Metabolic Parents LEarning ADAPTED BY THE DIETITIANS GROUP British Inherited Metabolic Diseases Group BASED ON THE ORIGINAL TEMPLE WRITTEN BY KOLKER AND BURGARD GA1 Information for
More informationCongenital myasthenic syndromes (CMS)
Congenital myasthenic syndromes (CMS) This fact sheet is for children and adults diagnosed with congenital myasthenic syndrome. It s a complex subject, so information has been adapted to suit all audiences.
More informationInfantile-onset glycogen storage disease type II
Case Report 379 Infantile-Onset Glycogen Storage Disease Type II (Pompe Disease): Report of a Case with Genetic Diagnosis and Pathological Findings Yao-Tun Teng, MD; Wen-Jen Su, MD; Jia-Wei Hou 1, MD,
More informationPackage leaflet: Information for the user
CSL Behring Package leaflet: Information for the user Alburex 5, 50 g/l, solution for infusion & Alburex 20, 200 g/l, solution for infusion Human albumin Read all of this leaflet carefully before you are
More informationNewborn Screening for Lysosomal Storage Diseases in Missouri. Outline
Newborn Screening for Lysosomal Storage Diseases in Missouri Dr. Kathy Grange Division of Genetics and Genomic Medicine Department of Pediatrics Washington University Outline Brief overview of clinical
More informationPATIENT INFORMATION LEAFLET AMLOC RANGE
SCHEDULING STATUS: S3 PROPRIETARY NAME AND DOSAGE FORM: AMLOC 5 mg tablets AMLOC 10 mg tablet Read all of this leaflet carefully before you start taking AMLOC. Keep this leaflet. You may need to read it
More informationAn information leaflet for patients and families. Von Hippel- Lindau Disease
An information leaflet for patients and families Von Hippel- Lindau Disease What is Von Hippel-Lindau disease? Von Hippel-Lindau (VHL) disease is a rare inherited disorder caused by a genetic alteration
More informationHow are unresolved Myasthenia Gravis symptoms disrupting your day? Talk to your doctor about your symptoms
How are unresolved Myasthenia Gravis symptoms disrupting your day? Talk to your doctor about your symptoms Recognize the symptoms of your generalized Myasthenia Gravis (gmg) Anti-acetylcholine receptor
More informationMultiple Sclerosis. What is multiple sclerosis? What is the cause? What are the symptoms?
What is multiple sclerosis? Multiple Sclerosis Multiple sclerosis (MS) is a disease of the central nervous system (the brain and spinal cord). Many people with multiple sclerosis are only mildly affected
More informationAbout general anaesthesia Day Surgery Unit Patient Information Leaflet
About general anaesthesia Day Surgery Unit Patient Information Leaflet Originator: Nahla Farid - Consultant Anaesthetist Date: November 2011 Version: 1 Date for Review: November 2014 DGOH Ref No: DGOH/PIL/00560
More informationDuct Dependant Congenital Heart Disease
Children s Acute Transport Service Clinical Guidelines Duct Dependant Congenital Heart Disease This guideline has been agreed by both NTS & CATS Document Control Information Author CATS/NTS Author Position
More informationHaemophagocytic lymphohistiocytosis (HLH)
HLH Haemophagocytic lymphohistiocytosis (HLH) Information for families hello@piduk.org 0800 987 8986 www.piduk.org About this leaflet This booklet has been produced jointly between PID UK, Great Ormond
More information*Monitor for significant side effects, especially symptoms of neurological or cardiovascular events.
Assessment Prior to administration: Obtain complete health history including allergies, drug history, and possible drug reactions Assess reason for drug administration such as presence/history of anemia
More informationPRODUCT MONOGRAPH. Pr MYOZYME. alglucosidase alfa (Recombinant human acid alpha-glucosidase) Lyophilized Powder 50 mg vial. Enzyme Replacement Therapy
PRODUCT MONOGRAPH Pr MYOZYME alglucosidase alfa (Recombinant human acid alpha-glucosidase) Lyophilized Powder 50 mg vial Enzyme Replacement Therapy Sanofi Genzyme, a division of Sanofi-Aventis Canada Inc.
More informationDuct Dependant Congenital Heart Disease
Children s Acute Transport Service Clinical Guidelines Duct Dependant Congenital Heart Disease Document Control Information Author CATS/NTS Author Position CC Transport Services Document Owner E. Polke
More informationOrganic Acid Disorders
Genetic Fact Sheets for Parents Organic Acid Disorders Screening, Technology, and Research in Genetics is a multi-state project to improve information about the financial, ethical, legal, and social issues
More informationCardiovascular Genetics Clinic Arrhythmia Questionnaire
Name: Address: Home Phone: Cell Phone: Email Address: Date of Birth: Primary Care Physician: Why have you been referred for a Cardiovascular Genetics Appointment? Have you had a genetics evaluation? If
More informationDisclosures. This speaker has indicated there are no relevant financial relationships to be disclosed.
Disclosures This speaker has indicated there are no relevant financial relationships to be disclosed. Parkinson s Disease, Huntington s Disease and ALS: A brief overview of three diagnoses Leo G. Rafail,
More informationAcute kidney injury. Information for patients Sheffield Teaching Hospitals
Acute kidney injury Information for patients Sheffield Teaching Hospitals page 2 of 12 Acute kidney injury You have been given this leaflet because you have had an episode of acute kidney injury (AKI).
More informationRisks of Smoking in Pregnancy
Information leaflet on Risks of Smoking in Pregnancy Routine Antenatal Carbon Monoxide Recording 1 Risks of Smoking during Pregnancy Smoking is the single greatest cause of ill health and premature death
More informationGuide to Understanding Metachromatic Leukodystrophy
Guide to Understanding Metachromatic Leukodystrophy 0845 389 9901 mps@mpssociety.org.uk www.mpssociety.org.uk Contents What is MLD? What causes MLD? Are there different forms of MLD? How common is MLD?
More informationGlycogen Storage Disease Type III also known as Cori or Forbe s Disease/Debrancher Enzyme Deficiency
Glycogen Storage Disease Type III also known as Cori or Forbe s Disease/Debrancher Enzyme Deficiency What is GSDIII? Glycogen Storage Disease type 3 is an inherited condition caused by a defect in a gene
More information